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Purpose: This study evaluated the influence of prognostic factors and whole brain radiotherapy (WBRT)
on overall survival (OS) of breast cancer (BC) patients with brain metastases (BM).
Methods and materials: Medical records of 730 BC patients diagnosed with BM from 2000 to 2014 at 17
institutions were retrospectively reviewed. OS was calculated from BM diagnosis. Median follow-up
duration was 11.9 months (range, 0.1e126.2).
Results: Median OS was 15.0 months (95% CI: 14.0e16.9). Patients with different BC-specific graded
prognostic assessment (GPA) scores showed significant differences (p< 0.001) in OS. In multivariate
analysis, histologic grade 3 (p¼ 0.014), presence of extracranial metastasis (p < 0.001), the number of BM
(>4; p¼ 0.002), hormone receptor negativity (p¼ 0.005), HER2-negativity (p¼ 0.003), and shorter time
interval (<30 months) between BC and BM diagnosis (p¼ 0.007) were associated with inferior OS. By
summing the b-coefficients of variables that were prognostic in multivariate analyses, we developed astases; CI, confidence interval; CT, computed tomography; Dx, diagnosis; ER, estrogen receptor; FSRT, fractionated
sessment; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; IDC, invasive ductal carcinoma; ILC,
nce status; KROG, Korean Radiation Oncology Group; MRI, magnetic resonance imaging; Op, operation; OS, overall
ropensity score matching; PR, progesterone receptor; RTOG, Radiation Therapy Oncology Group; SRS, single-fraction
erapy.
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Whole brain radiotherapyprognostic model that stratified patients into low-risk (0.673) and high-risk (>0.673) subgroups; the
high-risk subgroup had poorer median OS (10.1 months, 95% CI: 7.9e11.9 vs. 21.9 months, 95% CI: 19.5
e27.1, p< 0.001). Univariate and multivariate analyses of propensity score-matched patients diagnosed
with BM 30 months after BC diagnosis (n¼ 389, “late BM”) revealed that WBRT-treated patients
showed superior OS compared to non-WBRT-treated patients (p¼ 0.070 and 0.030, respectively).
Conclusion: Our prognostic model identified high-risk BC patients with BM who might benefit from
increased surveillance; if validated, our model could guide treatment selection for such patients. Patients
with late BM might benefit from WBRT as initial local treatment.
© 2019 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer (BC) is the second most common cause of brain
metastases (BM) [1]. Up to 30% of metastatic BC patients experience
BM during the disease course [2]. In these patients, the prognosis is
extremely poor and very heterogeneous by tumor molecular sub-
type [3]. Because BM can cause severe neurological impairment
that limit the patient’s quality of life [4], treatment of BM while
improving the patient’s survival/quality of life presents a major
clinical challenge [5].
The treatment choice of BM is currently determined by patient
and tumor characteristics, including patient performance status,
patient preference, comorbidities, size and the number of lesions,
anatomical location [6,7]. Surgery, single-fraction stereotactic
radiosurgery (SRS), and whole brain radiotherapy (WBRT) are the
most common currently-used local treatment modalities. Histori-
cally, WBRT or surgical resection (if appropriate) have been per-
formed [5].
WBRT causes neurocognitive deterioration [8e10]. In random-
ized clinical trials that analyzed the effect of SRS with or without
WBRT [8,10], patients receiving additional WBRT showed greater
deterioration of neurocognitive function than those treated with
SRS alone [8]. Notably, the omission of WBRT did not decrease
overall survival (OS), although patients treated with SRS alone had
a worse intracranial tumor progression rate [8]. Therefore, SRS is
generally considered the treatment of choice for patients with a
limited number of BM [11]. However, SRS is associated with certain
limitations, such as the number of SRSs that can be performed and
the shorter local failure-free survival when compared to WBRT
[8,10]. Tumor shrinkage due toWBRT was reported to be associated
with better survival and neurocognitive function preservation [12].
Hence, there is an unmet clinical need to develop tools that enable
selection of the appropriate patient group for these treatment
modalities.
We conducted a multicenter retrospective study to investigate
survival outcomes and prognostic factors affecting OS in BC pa-
tients with BM. This study also aimed to identify patients that
might show a significant survival benefit with WBRT as initial local
treatment.
2. Methods and Materials
2.1. Patients
We retrospectively analyzed medical records of BC patients
diagnosed with BM between 2000 and 2014 in 17 institutions. We
excluded patients with leptomeningeal seeding, history of other
types of malignancy before or after the diagnosis of BC, including
contralateral BC, or male BC. Finally, 730 patients were included in
this study. This study was approved by the Institutional Review
Board of each institution.
BM were primarily diagnosed by magnetic resonance imaging(MRI) alone (n¼ 629). Twenty-six patients were diagnosed via
computed tomography (CT) alone, and both imaging modalities
(MRI and CT) were used in 68 patients. In five patients, BM were
identified by brain positron emission tomography (PET). One pa-
tient underwent a biopsy and another patient incidentally was
diagnosed with BM, initially thought to be a meningioma, after
surgical resection. The median interval from primary BC to BM was
31.2 months (range, 0e178.8).
2.2. Tumor subtype classification
Using immunohistochemistry staining, a tumor showing estro-
gen receptor (ER) and/or progesterone receptor (PR)-positivity was
classified, if human epidermal growth factor receptor 2 (HER2)-
negative, as luminal A (i.e. HER2 negative, ER/PR positive), and
otherwise, as luminal B (i.e. HER2/ER/PR positive). The HER2-
enriched subtype was HER2-positive but, ER/PR-negative. Tumors
that were ER/PR/HER2-negative were categorized as triple-
negative BC.
2.3. Treatment
The most common first local treatment for BM was WBRT alone
(n¼ 430, 58.9%) followed by fractionated stereotactic radiotherapy
(FSRT) or SRS alone (n¼ 160, 21.9%). Twenty-seven patients (3.7%)
underwent surgical tumor resection alone, and others (n¼ 113,
15.5%) were treated with a combination of modalities (Table 1). The
median dose of WBRT was 30Gy in 3Gy per fraction. For FSRT, the
median prescribed dose of 36Gy was delivered in six fractions. The
dose of SRS was typically prescribed according to the guidelines of
each institution. The various cycles of systemic therapies were used
before and/or after local treatment. Seventy patients did not receive
systemic treatment. Among 319 patients with HER2-positive pri-
mary tumors, anti-HER2 treatment was used in 181 patients
(56.7%) during the disease course of BM.
2.4. Statistical analysis
OS was defined as the time interval between BM diagnosis and
death from any cause. We used the Kaplan-Meier method to esti-
mate OS rate and the log-rank test to compare survival between
groups. In univariate and multivariate analyses, Cox proportional
hazards models were constructed. For multivariate analysis, vari-
ables with p< 0.100 in univariate analyses were used as covariates.
For the multivariable prognostic model, the b-coefficients were
used for weighting according to the influence of the prognostic
factors on OS. We calculated each concordance index of BC-specific
graded prognostic assessment (GPA) and our prognostic model to
compare the predictability of OS.
For subgroup analysis, patients diagnosed with BM at least 30
months after the diagnosis of primary BC (n¼ 389) were defined as
“late BM” patients. To compare baseline characteristics between
Table 1
Baseline characteristics.
Characteristics (N¼ 730) No. %
Age at BM (year) Median (range) 50 23e85
Histologya Invasive ductal carcinoma 690 94.5
Invasive lobular carcinoma 6 0.8
Others 28 3.8
Histologic gradea 1e2 243 33.3
3 335 45.9
Hormone receptor status Negative 410 56.2
Positive 320 43.8
HER2 status Negative 411 56.3
Positive 319 43.7
Tumor subtype Luminal A 194 26.6
Luminal B 126 17.3
HER2-enriched 193 26.4
Triple-negative 217 29.7
Primary tumora Controlled 542 74.2
Uncontrolled 181 24.8
Extracranial metastasis Absent 115 15.8
Present 615 84.2
No. of BM 4 390 53.4
>4 340 46.6
Location of BM Supratentorial 240 32.9
Infratentorial 106 14.5
Both 384 52.6
Systemic therapy firsta No 303 41.5
Yes 426 58.4






Initial local treatment of BM WBRT alone 430 58.9
SRS or FSRT alone 160 21.9
Op alone 27 3.7
Op or SRS or FSRT / WBRT 83 11.4
WBRT / SRS 5 0.7
Others 25 3.4
aAvailable data only; Abbreviation: BM, brain metastasis; HER2, human epidermal
growth factor receptor 2; KPS, Karnofsky performance status; WBRT, whole brain
radiotherapy; SRS, Single-fraction stereotactic radiosurgery; FSRT, fractionated
stereotactic radiotherapy; Op, operation.
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n ¼ 278] as initial local treatment, the chi-squared or Fisher’s exact
test was used where appropriate, for categorical data, and Student’s
t-test was used for continuous data. Propensity score matching was
performed based on histology, HER2 status, tumor subtype, control
of primary tumor, the presence of extracranial metastasis, the
number of BM, the location of BM, and Karnofsky performance
status (KPS). A multivariable logistic regression model generated
the propensity score. The WBRT() and WBRT(þ) groups were
matched at a 1:1 ratio using the nearest neighbor method with a
caliper of 0.02. The conditional survival rate was the likelihood of
an additional 6-month survival, given that the patient has already
survived after BM diagnosis for 1, 1.5, 2, and 2.5 years, respectively.
A two-sided p-value <0.05 was considered statistically signifi-
cant. Statistical analyses were conducted using R project version
3.4.2 (https://www.r-project.org/), and the graph of conditional
survival rate was generated by Microsoft Excel 2013 (Redmond,
WA).3. Results
3.1. Patient characteristics
The median duration of follow-up after BM diagnosis was 11.9
months (range, 0.1e126.2). The baseline characteristics of 730patients are described in Table 1. About half of the patients (n¼ 335,
45.9%) had a high-grade tumor. Of the total patients, 320 patients
(43.8%) were positive for ER and/or PR, and HER2 were positive in
319 patients (43.7%). Primary tumor was controlled in 542 patients
(74.2%). Most patients (n¼ 615, 84.2%) had extracranial metastases.
According to the number of BM, 53.4% of patients (n¼ 390) had4,
and 46.6% (n¼ 340) had >4. There were 384 patients (52.6%) with
BM in both tentorial regions. Among patients, 638 patients (87.4%)
had neurologic symptoms at BM diagnosis: headache (n¼ 267);
weakness (n¼ 126); nausea/vomiting (n¼ 101); dizziness (n¼ 69);
ataxia (n¼ 59); conscious change (n¼ 44); visual disturbance
(n¼ 22); seizure (n¼ 22); and others (n¼ 16).
3.2. Patients with higher BC-specific GPA scores showed a higher OS
than those with lower GPA scores
Fig. 1A shows the Kaplan-Meier survival (OS) curves of the pa-
tients in this study. The median OS for all patients was 15.0 months
[95% confidence interval (CI), 14.0e16.9]. Patients’ OS rate was
analyzed using the BC-specific GPA system [13]. The GPA scoring
factors included KPS, tumor subtype, and age at BM diagnosis
(Table 2). Patients were divided into four groups according to their
GPA scores: GPA 0e1.0; 1.5e2.0; 2.5e3.0; and 3.5e4.0, respectively.
Median OS rates from the lowest to highest GPA score group were
8.3 (95% CI, 5.4e12.2), 10.4 (95% CI, 8.1e12.4), 20.7 (95% CI,
16.7e24.2), and 21.4 (95% CI, 18.1e30.0) months, respectively
(Fig. 1B). These differences were statistically significant (p< 0.001)
and the survival curves tended to separate into two groups based
on the threshold GPA score of 2 (median OS: GPA 0e2.0, 9.8
months; 95% CI, 7.9e11.8 vs. GPA 2.5e4.0, 20.8 months; 95% CI,
18.0e23.1, p< 0.001).
3.3. A novel multivariable prognostic model stratifies BC patients
with BM into risk groups with statistically significant differences in
OS
We conducted a multivariate analysis of OS using variables with
a p-value <0.100 in univariate analyses (Table 3) and found that
histologic grade 3 [hazard ratio (HR)¼ 1.327, 95% CI: 1.059e1.661,
p¼ 0.014], the presence of extracranial metastasis (HR¼ 2.379, 95%
CI: 1.734e3.260, p< 0.001), and the number of BM> 4 (HR¼ 1.519,
95% CI: 1.165e1.982, p¼ 0.002) were associated with poorer OS. A
longer time interval from primary BC to BM diagnosis (HR¼ 0.750,
95% CI: 0.608e0.825, p¼ 0.007), hormone receptor positivity
(HR¼ 0.724, 95% CI: 0.578e0.906, p¼ 0.005), and HER2 positivity
(HR¼ 0.730, 95% CI: 0.591e0.901, p¼ 0.003) were significantly
associated with superior OS in our multivariate analysis.
We developed a multivariable prognostic model by summing
the b-coefficients (detailed in Table 3) of statistically significant
variables from our multivariate analysis. Each patient who had
available data for these variables (n¼ 578) was scored according to
the presence or absence of prognostic factors. Patients were cate-
gorized as low-risk when the prognostic model score was 0.673,
while the remainder were considered as high-risk patients. There
was a significant (p< 0.001) difference in median OS between pa-
tients in the low-risk (median OS¼ 21.9 months; 95% CI: 19.5e27.1)
and high-risk (median OS¼ 10.1 months; 95% CI: 7.9e11.9) sub-
groups (Fig. 1C).
Among patients with GPA score 2 (n¼ 299), 84 patients were
categorized into the low-risk group of our prognostic model.
Ninety-nine patient in high GPA score (>2) group (n¼ 431) were
reclassified into the high-risk group. Using 578 patients, the
concordance index of BC-specific GPA with a cutoff of 2 was 0.700
(95% CI 0.652e0.749) and for our model was 0.726 (95% CI
0.680e0.773).
Fig. 1. Overall survival curve. (A) Whole cohort, (B) According to breast cancer specific-graded prognostic assessment, (C) According to our prognostic model.
Abbreviation: CI, confidence interval; BM, brain metastasis; GPA, graded prognostic assessment.
Table 2
Breast cancer specific-graded prognostic assessment (GPA).
Factors 0.0 0.5 1.0 1.5 2.0
KPS 50 60 70e80 90e100 e
Subtype Triple-negative e Luminal A HER2-enriched Luminal B
Age (year) 60 <60 e e e
Abbreviation: KPS, Karnofsky performance status; HER2, human epidermal growth
factor receptor 2.
J.S. Kim et al. / The Breast 49 (2020) 41e47443.4. Late BM patients may benefit from WBRT as initial local
treatment
Subgroup analyses were conducted to identify the patients who
would benefit from WBRT as initial local treatment for BM. The
number of patients with late BM by tumor subtype was as follows:
136 (70.1%) luminal A; 80 (63.5%) luminal B; 79 (40.9%) HER2-
enriched; and 94 (43.3%) triple-negative BC patients. Among late
BM patients, 111 patients did not receive initial WBRT [WBRT()
group], and 278 patients did [WBRT(þ) group] (Table 4). There was
a significant difference in histology distribution between the two
groups (p ¼ 0.046), but no difference in the proportions of patients
with different tumor subtypes (p ¼ 0.179). Primary tumor control
was excellent in patients without initial WBRT (85.6% vs. 77.0%,
p¼ 0.020). In patients who underwent initial WBRT, the proportion
of patients with >4 BM was higher (58.6% vs. 14.4%, p < 0.001) and
these BM tended to be located in both tentorial regions [WBRT(þ),Table 3
Univariate and multivariate Cox proportional hazards model for overall survival.
Univariate analysis
p value HR (95%
Age at BM 50 yr (vs. <50) 0.377 1.083 (0.9
Interval of primary Dx and BM 30 months (<30) 0.008 0.786 (0.6
Histology IDC (vs. others) 0.051 1.644 (0.9
Histologic grade 3 (vs. 1e2) 0.004 1.351 (1.1
Hormone receptor status positive (vs. negative) <0.001 0.679 (0.5
HER2 status positive (vs. negative) 0.002 0.754 (0.6
Triple-negative (vs. others) <0.001 1.674 (1.3
Primary tumor controlled (vs. uncontrolled) 0.002 0.724 (0.5
Extracranial metastasis present (vs. absent) <0.001 2.442 (1.8
No. of BM> 4 (vs. 4) <0.001 1.773 (1.4
Location of BM both (vs. supra- or infra-tentorial) <0.001 1.655 (1.3
Systemic therapy first yes (vs. no) 0.452 0.934 (0.7
KPS <70 (vs. 70) <0.001 1.411 (1.1
Initial WBRT yes (vs. no) 0.002 1.369 (1.1
Abbreviation: HR, hazard ratio; CI, confidence interval; BM, brain metastasis; Dx, diagnosi
KPS, Karnofsky performance status; WBRT, whole brain radiotherapy.
a Also known as a log hazard ratio.60.4% vs. WBRT(), 23.4%, p < 0.001]. In order to balance the two
groups, propensity score matching was performed using variables
with a p-value less than 0.200. Eighty-one patients in each group
were successfully matched (Table 4).
In the matched cohort, WBRT(þ) patients had a better OS
compared to WBRT() patients (median OS, 25.2 vs. 19.2 months,
p ¼ 0.068) (Fig. 2A). In terms of conditional survival, as patients
receiving WBRT survived longer, the additional 6-month survival
rate also increased (Fig. 2B). In multivariate analysis of the matched
cohort (Table 5), initial use of WBRT was a favorable prognostic
factor (HR¼ 0.621, 95% CI: 0.404e0.955, p¼ 0.030). The presence of
extracranial metastasis, was associatedwith poorer OS (HR¼ 8.683,
95% CI: 2.124e35.498, p¼ 0.003). In this cohort, patients with low
KPS had a poor prognosis (HR¼ 1.739, 95% CI: 1.103e2.740,
p¼ 0.017), but the number and location of BM did not affect OS
(p¼ 0.267 and 0.113, respectively).
We additionally conducted subgroup analyses of patients with
early BM (<30months) in order to identify the same effect ofWBRT.
However, in the propensity score-matched cohort, there was no
difference in OS between WBRT() and WBRT(þ) group
(p ¼ 0.180).
4. Discussion
BC patients with BM have a poor prognosis, and the prognosis
varies according to the tumor molecular subtype. Also, several
systemic and local treatment modalities are available for BM.Multivariate analysis
CI) p value HR (95% CI) b-coefficienta
07e1.293)
59e0.938) 0.007 0.750 (0.608e0.825) 0.288
98e2.707) 0.059 2.366 (0.970e5.772)
04e1.653) 0.014 1.327 (1.059e1.661) 0.283
66e0.814) 0.005 0.724 (0.578e0.906) 0.324
31e0.902) 0.003 0.730 (0.591e0.901) 0.315
84e2.024)
93e0.884) 0.509 0.918 (0.713e1.183)
41e3.239) <0.001 2.379 (1.734e3.260) 0.867
83e2.119) 0.002 1.519 (1.165e1.982) 0.418
84e1.980) 0.156 1.198 (0.933e1.536)
82e1.116)
74e1.696) 0.124 1.194 (0.915e1.507)
25e1.666) 0.207 1.174 (0.915e1.507)
s; IDC, invasive ductal carcinoma; HER2, human epidermal growth factor receptor 2;
Table 4
Baseline characteristics of patients with late brain metastasis before and after propensity score matching.
Before PSM After PSM
WBRT(), N¼ 111 WBRT(þ), N ¼ 278 WBRT(), N¼ 81 WBRT(þ), N ¼ 81
Characteristics No. % No. % p value No. % No. % p value
Age at BM (year)
Median (range) 50 (31e80) 51 (28e85) 0.877 49 (31e74) 49 (32e70) 0.564
Histologya 0.046 0.840
IDC 100 90.1 264 95.0 78 96.3 76 93.8
ILC 2 1.8 1 0.4 1 1.2 1 1.2
Others 9 8.1 9 3.2 2 2.5 4 4.9
Histologic gradea 1.000 0.803
1e2 48 43.2 108 38.8 32 39.5 33 40.7
3 49 44.1 113 40.6 37 45.7 33 40.7
Hormone receptor status 0.246 0.528
Negative 55 49.5 118 42.4 34 42.0 39 48.1
Positive 56 50.5 160 57.6 47 58.0 42 51.9
HER2 status 0.180 0.631
Negative 72 64.9 158 56.8 50 61.7 46 56.8
Positive 39 35.1 120 43.2 31 38.3 35 43.2
Tumor subtype 0.179 0.726
Luminal A 37 33.3 99 35.6 31 38.3 28 34.6
Luminal B 19 17.1 61 21.9 16 19.8 14 17.3
HER2-enriched 20 18.0 59 21.2 15 18.5 21 25.9
Triple-negative 35 31.5 59 21.2 19 23.5 18 22.2
Primary tumora 0.020 0.585
Controlled 95 85.6 214 77.0 70 86.4 68 84.0
Uncontrolled 13 11.7 62 22.3 11 13.6 12 14.8
Extracranial metastasis 0.102 1.000
Absent 16 14.4 23 8.3 7 8.6 7 8.6
Present 95 85.6 255 91.7 74 91.4 74 91.4
No. of BM <0.001 1.000
4 95 85.6 115 41.4 66 81.5 65 80.2
>4 16 14.4 163 58.6 15 18.5 16 19.8
Location of BM <0.001 1.000
Supra- or Infra-tentorial 85 76.6 110 39.6 58 71.6 58 71.6
Both 26 23.4 168 60.4 23 28.4 23 28.4
Systemic therapy firsta 0.590 0.230
No 38 34.2 107 38.5 23 28.4 31 38.3
Yes 73 65.8 170 61.2 58 71.6 49 60.5
KPS 0.053 1.000
<70 82 73.9 175 62.9 60 74.1 59 72.8
70 29 26.1 103 37.1 21 25.9 22 27.2
Abbreviation: PSM, propensity score matching; BM, brain metastasis; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; HER2, human epidermal growth factor
receptor 2; KPS, Karnofsky performance status.
a Available data only.
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optimal treatment selection for each patient.
In the current study, the median OS of BC patients with BM was
15.0 months, and OS of patients with the highest BC-specific GPA
score group was the best. WBRT was the most commonly used
initial local treatment in Korea. The prognostic model we devel-
oped in our study revealed that there was a significant difference in
survival between low- and high-risk patient subgroups. We also
confirmed that WBRT significantly improved the OS of patients
with late BM.
Previous studies have delineated several factors that are
significantly prognostic in BC patients with BM, including a high-
grade tumor, ER/PR-negativity, and the presence of liver and lung
metastases [14]. Our results were consistent with these reports as
we found that patients with histologic grade 3 or hormone
receptor-negative tumors had an unfavorable prognosis. Patients
with a small number of BM or without extracranial metastases also
tended to survive longer.
A longer interval from primary BC to BM was associated with
superior OS. This result can be explained by the fact that many
patients in this study with late onset of BM had tumor subtypes
with favorable prognostic features, such as luminal A tumor sub-
type. It was also known that triple-negative or HER2-enrichedtumors, which showed worse prognoses, were associated with
earlier BM development compared to luminal A tumors [14,15].
However, in our study, the presence of a HER2-positive tumor was a
good prognosis factor after developing BM. In a retrospective study,
Niikura et al. also reported that BM patients with HER2-positive
tumors had longer OS than those with HER2-negative tumors
[16]. Anti-HER2 treatments, especially trastuzumab, effectively
controlled extracranial metastases and resulted in survival
improvement in these patients [16e19].
Whenwe categorized patients into four groups according to the
BC-specific GPA score [13], OS improved with an increase in pa-
tients’ GPA scores. Furthermore, the Kaplan-Meier survival curves
of the GPA score groups clustered into two groups were based on
the threshold GPA score of 2. Except for the highest GPA score
group, the OS of patients in the GPA score groups in our study were
better than those (3.4, 7.7, 15.1, and 25.3 months, respectively) re-
ported by Sperduto et al. [13]. This increased median OS should,
however, be interpreted with caution, since treatment modalities
and supportive care of patients have improved over time. There-
fore, a new model is needed to better predict the survival rate.
We explored a prognostic model that utilized the b-coefficients
of factors that were prognostic in our multivariable analyses. We
found that this model stratified the patients in our study into a
Fig. 2. (A) Overall survival curve and (B) 6-month conditional survival rate according to initial whole brain radiotherapy in patients with late brain metastasis after propensity score
matching.
Error bar means a 95% confidence interval.
Abbreviation: WBRT, whole brain radiotherapy; BM, brain metastasis.
Table 5
Univariate and multivariate Cox proportional hazards model for overall survival of patients with late brain metastasis after propensity score matching.
Univariate analysis Multivariate analysis
p value HR (95% CI) p value HR (95% CI)
Age at BM 50 yr (vs. <50 yr) 0.329 1.217 (0.820e1.807)
Histology IDC (vs. others) 0.355 1.722 (0.544e5.451)
Histologic grade 3 (vs. 1e2) 0.326 1.246 (0.803e1.934)
Hormone receptor status positive (vs. negative) 0.390 0.840 (0.565e1.250)
HER2 status positive (vs. negative) 0.440 0.854 (0.572e1.275)
Triple-negative (vs. others) 0.269 1.310 (0.812e2.114)
Primary tumor controlled (vs. uncontrolled) 0.323 0.762 (0.445e1.306)
Extracranial metastasis present (vs. absent) 0.004 7.907 (1.941e32.220) 0.003 8.683 (2.124e35.498)
No. of BM> 4 (vs. 4) 0.010 1.884 (1.166e3.044) 0.267 1.384 (0.780e2.455)
Location of BM both (vs. supra- or infra-tentorial) 0.006 1.824 (1.192e2.792) 0.113 1.471 (0.912e2.372)
Systemic therapy first yes (vs. no) 0.835 0.957 (0.632e1.448)
KPS <70 (vs. 70) 0.005 1.833 (1.198e2.805) 0.017 1.739 (1.103e2.740)
Initial WBRT yes (vs. no) 0.070 0.684 (0.454e1.032) 0.030 0.621 (0.404e0.955)
Abbreviation: HR, hazard ratio; CI, confidence interval; BM, brainmetastasis; IDC, invasive ductal carcinoma; HER2, human epidermal growth factor receptor 2; KPS, Karnofsky
performance status; WBRT, whole brain radiotherapy.
J.S. Kim et al. / The Breast 49 (2020) 41e4746high-risk subgroup that a significantly poorer OS compared to the
low-risk subgroup. Therewere shifts in the patients who had a poor
prognosis in the BC-specific GPA system into the low-risk group in
our prognostic model, vice versa. After calculating the concordance
index of each model, we found that our prognostic model tended to
predict OS slightly better, although further validation would be
required. Hence, our model identified high-risk patients that
require more aggressive treatments and close surveillance after
initial treatment of BM.
In univariate analysis, the survival of patients receivingWBRT as
first local treatment was poor. However, as WBRT is mainly per-
formed in cases with larger intracranial or extracranial tumor
burden [11], this result was reasonable. Conversely, our multivar-
iate analysis did not show any significant difference in OS between
WBRT(þ) and WBRT() patients.
In subgroup analysis, late BM patients were found to benefit
from WBRT. This is the first study to examine OS differences in BC
patients based on the time of onset of BM and receipt of WBRT.
Among late BM patients, patients treated with WBRT as the first
local treatment had more known risk factors, including a higher
number of BM, than those who did not receive this treatment. After
propensity score matching betweenWBRT() andWBRT(þ) group,OS curves showed marginally significant (p ¼ 0.068) difference
between groups, and crossed over each other at around 9 months
after BM diagnosis. The conditional survival rate was also not
significantly different between the two groups for up to 2 years,
although the difference became significant at 2.5 years. To address
the caveat that propensity score matchingmay not have adequately
corrected imbalances between the two groups, we performed
multivariable analyses and found a significant increase in OS
associated with late BM patients receiving WBRT. However, inter-
pretation of these results should be with caution due to the small
number of patients.
The “seed and soil” model proposed by Steven Paget [20] hy-
pothesizes that cross-talk between metastatic tumor cells (seed)
and each organ’s microenvironment (soil) ultimately underlies
metastasis. As previously mentioned, early BM were characterized
by aggressive tumor subtypes. When micrometastases occur, they
proliferates rapidly to result in a lesion that is either observable by
imaging or symptomatic, so an early BM diagnosis is possible.
However, late BMmay be detected after multiple micrometastases.
In other words, because there are micrometastases in many parts of
the brain, WBRT would be more helpful rather than SRS/FSRT or
surgical resection, which treat only currently-visible lesions.
J.S. Kim et al. / The Breast 49 (2020) 41e47 47Despite this being a large multicenter cohort study, the retro-
spective design of this study has its limitations. Furthermore,
external validation of our multivariable prognostic model is
required. Additionally, we were unable to analyze data pertaining
to the volume of the treated lesions and neurotoxicity, which all
have clinical significance. Finally, patients were treated with
various types of systemic agents that were not factored into our
analyses; so the outcomes of local treatment for BM requires
cautious interpretation.
Currently, the RTOG 1119 trial (NCT01622868), a phase II ran-
domized controlled study, compares the efficacy of using lapatinib
in WBRT/SRS patients with BM from HER2-positive BC. From this
study, we would expect more detailed outcomes of local treatment
(WBRT vs. SRS) as well as the efficacy of concurrent use of lapatinib
for BM treatment. Furthermore, to overcome the decline of neu-
rocognitive function after WBRT, hippocampal sparing (HS)-WBRT
has been proposed as an alternative [21,22]. Indeed, in a prospec-
tive study of 24 patients, HS-WBRT was performed for therapeutic
or prophylactic purposes, and the dosimetric parameters for the
left-sided hippocampus were related to the immediate recall of
verbal memory [23]. Therefore, as an initial local treatment, HS-
WBRT rather than SRS could be used for patients, especially with
late BM.
5. Conclusions
Our prognostic model identified high-risk BC patients who
might benefit from increased surveillance for disease progression
and more aggressive treatment of their BM; if validated, our model
could guide treatment selection for these patients. Our study found
that patients with late BM might benefit fromWBRT as initial local
treatment.
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